Shopping Cart
- Remove All
- Your shopping cart is currently empty
EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $69 | In Stock | |
5 mg | $172 | In Stock | |
10 mg | $286 | In Stock | |
25 mg | $473 | In Stock | |
50 mg | $648 | In Stock | |
100 mg | $888 | In Stock |
Description | EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC. |
In vitro | In A549, PC9, H1975, CL68, and CL97 cells, EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. EGFR-IN-8 (0-20 μM; 24, 48, 72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97 cells at different time intervals, with IC50 values ranging from 0.3 to 0.6 μM and 0.2-0.5 μM after 48 and 72 h of treatment respectively[1]. |
In vivo | EGFR-IN-8 (50,150 mg/kg; oral gavage) exhibits suppression (29% and 60%, respectively) of H1975 xenograft tumor growth in a dose-dependent manner[1]. |
Molecular Weight | 662.02 |
Formula | C32H23ClF3N7O4 |
Cas No. | 2407957-87-1 |
Smiles | FC(F)(F)c1cc(NC(=O)Nc2cccc(c2)-c2nc(no2)-c2ccc(NC(=O)c3cccnc3)cc2Cl)ccc1NC(=O)C1CC1 |
Relative Density. | 1.540 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: <1 mg/mL (insoluble or slightly soluble), Sonication is recommended. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.